(Q39662629)

13 September 2017

title

The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib (English)

1 reference

13 September 2017

main subject

hepatocellular carcinoma

1 reference

1 reference

4

1 reference

13 September 2017

2

Tetsuo Takehara

1 reference

13 September 2017

13

Naoki Hiramatsu

1 reference

13 September 2017

9

Tomohide Tatsumi

1 reference

13 September 2017

8

Takuya Miyagi

1 reference

13 September 2017

Hayato Hikita

1

1 reference

13 September 2017

Satoshi Shimizu

3

1 reference

13 September 2017

Minoru Shigekawa

5

1 reference

13 September 2017

Kyoko Iwase

6

1 reference

13 September 2017

Atsushi Hosui

7

1 reference

13 September 2017

Hisashi Ishida

10

1 reference

13 September 2017

Wei Li

11

1 reference

13 September 2017

Tatsuya Kanto

12

1 reference

13 September 2017

Norio Hayashi

14

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

13 September 2017

1 reference

13 September 2017

volume

52

1 reference

13 September 2017

issue

4

1 reference

13 September 2017

page(s)

1310-1321

1 reference

Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice

13 September 2017

cites work

1 reference

Cell death regulation by the Bcl-2 protein family in the mitochondria

21 January 2018

1 reference

7 January 2021

Bcl-2 family proteins and cancer

1 reference

7 January 2021

Expression and role of Bcl-xL in human hepatocellular carcinomas

1 reference

7 January 2021

Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma

1 reference

7 January 2021

Prognostic significance of Bcl-xL in human hepatocellular carcinoma

1 reference

7 January 2021

Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses.

1 reference

7 January 2021

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

7 January 2021

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

1 reference

7 January 2021

Piercing the armor of hepatobiliary cancer: Bcl-2 homology domain 3 (BH3) mimetics and cell death.

1 reference

7 January 2021

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.

1 reference

7 January 2021

Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer

1 reference

7 January 2021

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

1 reference

7 January 2021

Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver

1 reference

7 January 2021

The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma

1 reference

7 January 2021

BH3-only protein bid participates in the Bcl-2 network in healthy liver cells

1 reference

7 January 2021

Programmed anuclear cell death delimits platelet life span.

1 reference

7 January 2021

Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy

1 reference

7 January 2021

Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis

1 reference

7 January 2021

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

1 reference

7 January 2021

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

1 reference

7 January 2021

Apoptosis and cancer: the genesis of a research field

1 reference

7 January 2021

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

1 reference

7 January 2021

RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway

1 reference

7 January 2021

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.

1 reference

7 January 2021

A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.

1 reference

7 January 2021

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

1 reference

7 January 2021

'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

1 reference

7 January 2021

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

1 reference

7 January 2021

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines

1 reference

7 January 2021

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.

1 reference

7 January 2021

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

1 reference

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.23836

1 reference

13 September 2017

1 reference